Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.88 |
| ▸ | HMGCR | P04035 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | ACLY | P53396 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | SLC13A5 | Q86YT5 | 7/20 | 0.41 |
| ▸ | CPT2 | P23786 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL27651029 | 1.00 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL27906911 | 1.00 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL28110675 | 1.00 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL10407698 | 0.97 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL29395328 | 0.97 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL9299268 | 0.94 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL20536693 | 0.94 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL22734240 | 0.94 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL9392300 | 0.94 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL7995770 | 0.94 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 331 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113425835-B | Growth hormone crude drug solution, water injection and preparation method thereof | 常州健益生物制药有限公司 | 2024-03-19 | — | — | CN | claimed |
| US-11445744-B2 | Tobacco beads | ALTRIA CLIENT SERVICES LLC (US) | 2022-09-20 | — | — | US | claimed |
| CN-114698684-A | Plum freeze-drying process | 四川轻化工大学 | 2022-07-05 | — | — | CN | claimed |
| CN-111848776-B | Polyethylene glycol modified rhBNP and preparation method thereof | 江苏璟泽生物医药有限公司 | 2022-03-18 | — | — | CN | claimed |
| CN-112481343-B | Method for producing collagen peptide by using cod skin raw material | 山东恒鑫生物科技有限公司 | 2022-03-18 | — | — | CN | claimed |
| CN-113425835-A | Growth hormone raw material medicine solution, water injection and preparation method thereof | 常州健益生物制药有限公司 | 2021-09-24 | — | — | CN | claimed |
| CN-112481343-A | Method for producing collagen peptide by using cod skin raw material | 山东恒鑫生物科技有限公司 | 2021-03-12 | — | — | CN | claimed |
| US-10343995-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-07-09 | — | — | US | claimed |
| US-20190047957-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-02-14 | — | — | US | claimed |
| US-10106503-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-10-23 | — | — | US | claimed |
| CN-105950257-A | Decoking descaling agent for pulverized coal fired boiler | 无锡锡能锅炉有限公司 | 2016-09-21 | — | — | CN | claimed |
| CN-102478557-A | Special protein A immunoadsorption kit for chromatography | DALIAN CHUANGDA TECH TRADE MK | 2012-05-30 | — | — | CN | claimed |
| US-7355029-B2 | Genes encoding carbon metabolism and energy-producing proteins | BASF AG (DE) | 2008-04-08 | — | — | US | claimed |
| CN-101122562-A | Oligonucleotide chip for detecting transplanted kidney function and its uses | UNIV ZHEJIANG (CN) | 2008-02-13 | — | — | CN | claimed |
| CN-1544460-A | Protein A immunoadsorption medium regeneration and utilization process | 浙江科锐生物科技有限公司 | 2004-11-10 | — | — | CN | claimed |
| CN-1544459-A | Preparation method of solution for chromatographic column and protein A immunoadsorption medium | 浙江科锐生物科技有限公司 | 2004-11-10 | — | — | CN | claimed |
| US-6037173-A | NUCLEIC ACID MOLECULE THAT CODES A THYROID RECEPTOR BINDING PROTEIN; FOR DIAGNOSIS AND TREATMENT OF DISEASES ASSOCIATED WITH DEFECTS IN THE FUNCTION OF THYROID BINDING PROTEIN; FOR DETECTION OF MUDULATORS OF PROTEIN FUNCTION | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2000-03-14 | — | — | US | claimed |
| US-5466781-A | Isolation of bodies, suspension, agitation and centrifuging | CHIRON THERAPEUTICS (US) | 1995-11-14 | — | — | US | claimed |
| EP-0031826-B1 | PROCESS FOR MONITORING THE HISTORY OF TEMPERATURE VERSUS TIME OF DEEP-FROZEN PRODUCT, INDICATOR FOR APPLYING SAID PROCESS AND UTILIZATION OF SAID PROCESS | ALLMENDINGER, Thomas (CH) | 1984-05-30 | — | — | EP | claimed |
| US-4404132-A | FREE OF THROMBIN, HEPARIN, THROMBOPLASTIN ACTIVITY | CUTTER LABORATORIES, INC. (US) | 1983-09-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190047957-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM3 | MEN1 747/4885ALDH1A1 1082/4885HMGCR 2052/4885 |
| US-10343995-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | MEN1 747/4885ALDH1A1 1082/4885HMGCR 2052/4885 |
| US-10106503-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | MEN1 747/4885ALDH1A1 1082/4885HMGCR 2052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.